Radiofrequency Ablation Therapy in Patients with Breast Cancers Two Centimeters or Less in Size

この論文にアクセスする

この論文をさがす

著者

    • OURA Shoji
    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University
    • TAMAKI Takeshi
    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University
    • HIRAI Issei
    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University
    • YOSHIMASU Tatsuya
    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University
    • OHTA Fuminori
    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University
    • NAKAMURA Rie
    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University
    • OKAMURA Yoshitaka
    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University

抄録

Background: Non-surgical ablation is an attractive approach as a local control method for breast cancer. The purpose of this study was to investigate the complications and efficacy of radiofrequency ablation (RFA) therapy for breast cancer.<BR>Methods: A total of 52 patients with breast cancer were enrolled. The mean tumor size was 1.3 cm (range, 0.5-2.0 cm). Under general anesthesia, RFA was done with a Cool-tip RF system after sentinel node biopsy. All patients received one session of RFA, for a maximum time of 30 minutes for the first 29 patients and 15 minutes for the following 23 patients when so-called 'break', i.e. stopping the delivery of radiofrequency, did not occur. Postoperative cytological evaluation was done 3-4 weeks after operation. Adjuvant therapy consisted of chemo- and/or endocrine-therapy and radiotherapy (50Gy).<BR>Results: The mean time of RFA was 12 minutes (5-25 minutes). One patient (2%) was troubled with a skin burn just above the ablated field. No patient had viable cancer cells on post-operative cytological evaluation. No recurrence developed 15 months on the average after RFA (6-30 months). Cosmesis after RFA was excellent in 43 patients (83%), good in 6 (12%), and fair in 3 (6%).<BR>Conclusion: RFA can be safely used for breast cancer and provides good local control and excellent cosmesis to patients with small breast cancers.

収録刊行物

  • Breast cancer : the journal of the Japanese Breast Cancer Society  

    Breast cancer : the journal of the Japanese Breast Cancer Society 14(1), 48-54, 2007-01-01 

    The Japanese Breast Cancer Society

参考文献:  17件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  5件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10018815302
  • NII書誌ID(NCID)
    AA1103354X
  • 本文言語コード
    ENG
  • 資料種別
    REV
  • ISSN
    13406868
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ